Feverfew for preventing migraine
Wider B, Pittler MH, Ernst E
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane systematic review of double-blind placebo-controlled trials of feverfew monopreparations for migraine prevention, searched to January 2015.
Key Findings
The largest rigorous trial (n=218) found a difference of only 0.6 attacks per month versus placebo, with no significant differences in intensity, duration, nausea or global assessment; two earlier rigorous trials were negative.
Conclusions
Evidence for feverfew is low quality and only marginally positive; larger rigorous trials with standardized extracts are needed before firm conclusions.
Limitations
Few trials, mixed extract preparations, small samples in positive trials, low-quality evidence overall.
Outcomes Measured
There is insufficient evidence from randomised, placebo-controlled trials to suggest an effect of feverfew over and above placebo for preventing migraine.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Cochrane Collaboration
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.